Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade B 81.4 -2.83% -2.37
ARGX closed down 2.83 percent on Friday, October 19, 2018, on 61 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Oct 25

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ARGX trend table...

Date Alert Name Type % Chg
Oct 19 200 DMA Resistance Bearish 0.00%
Oct 19 Fell Below 50 DMA Bearish 0.00%
Oct 19 Stochastic Sell Signal Bearish 0.00%
Oct 19 Overbought Stochastic Strength 0.00%
Oct 19 Upper Bollinger Band Touch Strength 0.00%
Oct 18 200 DMA Resistance Bearish -2.83%
Oct 18 Crossed Above 50 DMA Bullish -2.83%
Oct 18 Pocket Pivot Bullish Swing Setup -2.83%
Oct 18 Calm After Storm Range Contraction -2.83%
Oct 18 Above Upper BB Strength -2.83%

Older signals for ARGX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 103.0
52 Week Low 22.21
Average Volume 279,863
200-Day Moving Average 84.2118
50-Day Moving Average 83.3246
20-Day Moving Average 74.947
10-Day Moving Average 74.519
Average True Range 4.0423
ADX 22.1
+DI 31.5333
-DI 22.4155
Chandelier Exit (Long, 3 ATRs ) 73.4231
Chandelier Exit (Short, 3 ATRs ) 75.9369
Upper Bollinger Band 83.563
Lower Bollinger Band 66.331
Percent B (%b) 0.87
BandWidth 22.992248
MACD Line -1.3233
MACD Signal Line -3.0771
MACD Histogram 1.7538
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -64.09
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 87.36
Resistance 3 (R3) 87.70 86.06 86.36
Resistance 2 (R2) 86.06 84.54 85.89 86.03
Resistance 1 (R1) 83.73 83.61 82.91 83.39 85.70
Pivot Point 82.09 82.09 81.68 81.92 82.09
Support 1 (S1) 79.76 80.57 78.94 79.42 77.10
Support 2 (S2) 78.12 79.64 77.95 76.77
Support 3 (S3) 75.79 78.12 76.44
Support 4 (S4) 75.45